Michael Sardano is President & CLO at Sensus Healthcare, Inc. (SRTS). They have made 9 open-market trades across 1 company since 2022, most recently 2025-12-12.
CIK 0001720602
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
8 open-market purchases totalling $32K since 2023, against 1 sale. Across 8 scored buys the stock is down 2.6% at ninety days, and 5.1 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SRTS | 158,839 | $440K |
Shares reported on the most recent Form 4, priced at the 2025-12-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 13% | 0% | 38% |
| Avg Move | -5.8% | -12.6% | -2.6% |
| Alpha | -6.4% | -12.7% | -5.1% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRTS | BUY | 2025-11-18 | 2025-11-19 | $3.80 | $4K | -2.2% | -7.7% | -7.7% |
| SRTS | BUY | 2025-11-11 | 2025-11-18 | $4.27 | $9K | -2.2% | -6.1% | -6.4% |
| SRTS | BUY | 2025-11-11 | 2025-11-13 | $4.24 | $992 | -3.4% | -16.3% | +7.9% |
| SRTS | BUY | 2025-08-13 | 2025-08-14 | $3.37 | $3K | -4.4% | -8.4% | +33.7% |
| SRTS | BUY | 2025-02-10 | 2025-02-10 | $5.95 | $6K | -12.9% | -25.9% | -26.4% |
| SRTS | BUY | 2023-08-28 | 2023-08-28 | $2.99 | $3K | -1.4% | -8.3% | -12.8% |
| SRTS | BUY | 2023-08-08 | 2023-08-08 | $3.78 | $4K | -20.7% | -26.0% | -42.9% |
| SRTS | BUY | 2023-05-08 | 2023-05-10 | $3.00 | $3K | +0.7% | -2.0% | +33.4% |
| SRTS | SELL | 2022-09-13 | 2022-09-15 | $14.13 | $71K | -18.3% | -13.1% | -53.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.